It is not clear whether HER2-low tumors represent distinct subtypes of breast cancer with unique biological characteristics, and moreover, whether HER2-low early-stage breast cancer patients have different clinicopathological characteristics with different survival outcomes compared to HER2-0 patients. This evidence concerns the gene ERBB2 and breast carcinoma.